Placebo for sitagliptin

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Theracos

Conditions

Diabetes Mellitus, Type 2HIV-1 InfectionRenal Insufficiency, ChronicType 2 Diabetes Mellitus

Phase 2

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

CompletedNCT00631488

Merck Sharp & Dohme LLCDiabetes Mellitus, Type 2

Start: 2008-02-29End: 2009-01-31Updated: 2017-01-02

Sitagliptin for Reducing Inflammation and Immune Activation

CompletedNCT02513771

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsHIV-1 Infection

Start: 2015-09-30End: 2017-01-10Updated: 2018-06-18

Phase 3

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

CompletedNCT00509262

Merck Sharp & Dohme LLCDiabetes Mellitus, Type 2, Renal Insufficiency, Chronic

Start: 2007-10-09End: 2011-03-16Updated: 2017-05-12

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

CompletedNCT03115112

TheracosType 2 Diabetes Mellitus

Start: 2017-10-12End: 2018-10-31Updated: 2021-06-22

Related Papers

Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial.

2017-05-1516 citations